{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:36:57Z","timestamp":1777379817976,"version":"3.51.4"},"reference-count":115,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["AIDS Research and Human Retroviruses"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:p>\n                    Rosuvastatin therapy might have an effect on the inflammatory and coagulation biomarkers. However, the evidence about the effect of rosuvastatin therapy on the high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), and D-dimer levels among people living with human immunodeficiency virus (PLHIV) is still unclear. Therefore, this study investigated the relational effect of rosuvastatin therapy on serum\/plasma hsCRP, IL-6 and D-dimer levels in PLHIV. The literature search was done from Embase, PubMed, and Web of Science databases. The review and meta-analysis included studies written in English language up to January 4, 2020. Random effects model was used to evaluate the pooled standard mean difference with 95% confidence interval. A meta-analysis was performed using nine articles with 392 PLHIV. The result revealed that the plasma\/serum levels of IL-6 were significantly reduced after the intervention. However, hsCRP and D-dimer levels showed no significant difference (\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    \u2009&gt;\u2009.05) between before and after the intervention. The subgroup analysis showed that there was significant association between PLHIV ages &lt;45 years and cohort studies with IL-6 levels. The current CD4\n                    <jats:sup>+<\/jats:sup>\n                    counts \u2265350 cells\/mm\n                    <jats:sup>3<\/jats:sup>\n                    correlated with hsCRP as well as IL-6. Similarly, nadir CD4\n                    <jats:sup>+<\/jats:sup>\n                    counts \u2265200 cells\/mm\n                    <jats:sup>3<\/jats:sup>\n                    and duration of HIV diagnosis &lt;10 years also showed significant association with IL-6 and D-dimer levels. It was also indicated that participants who were under antiretroviral drug for &lt;7 years were significantly associated with hsCRP levels. This study established that IL-6 levels were significantly reduced after the intervention while hsCRP and D-dimer levels showed no significant difference between before and after the intervention.\n                  <\/jats:p>","DOI":"10.1089\/aid.2020.0273","type":"journal-article","created":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T11:01:05Z","timestamp":1619694065000},"page":"821-833","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["The Effect of Rosuvastatin on Plasma\/Serum Levels of High-Sensitivity C-Reactive Protein, Interleukin-6, and D-Dimer in People Living with Human Immunodeficiency Virus: A Systematic Review and Meta-Analysis"],"prefix":"10.1177","volume":"37","author":[{"given":"Akililu Alemu","family":"Ashuro","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin-Guang","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, China."},{"name":"Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan-Sheng","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Sheng","family":"Di","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, China."},{"name":"Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Napoleon Bellua","family":"Sam","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai-Feng","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, China."},{"name":"Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6604-9614","authenticated-orcid":false,"given":"Dong-Qing","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, China."},{"name":"Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,11,5]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-019-00478-x"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4643-6"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002468"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2017.09.030"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2016.4728"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-018-0400-5"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-013-0168-6"},{"key":"e_1_3_5_9_2","first-page":"21","article-title":"Increased non-AIDS mortality among persons with AIDS-defining events after antiretroviral therapy initiation","author":"Pettit AC","year":"2018","unstructured":"Pettit AC, , Giganti MJ, , Ingle SM, et al.: Increased non-AIDS mortality among persons with AIDS-defining events after antiretroviral therapy initiation. J Int AIDS Soc, 2018; 21.","journal-title":"J Int AIDS Soc"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-018-3637-0"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2015.06.086"},{"key":"e_1_3_5_12_2","first-page":"60","article-title":"Low prevalence of calcified coronary plaque among Ugandans with and without HIV infection: Comparison with a United States cohort and associations with biomarkers of inflammation","volume":"21","author":"Longenecker CT","year":"2018","unstructured":"Longenecker CT, , Alencherry B, , Erem G, et al.: Low prevalence of calcified coronary plaque among Ugandans with and without HIV infection: Comparison with a United States cohort and associations with biomarkers of inflammation. J Int Aids Soc, 2018; 21:60\u201361.","journal-title":"J Int Aids Soc"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.11648\/j.ijhpebs.20180401.12"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy205"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001917"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.115.004430"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0214735"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001149"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-63849-6.00015-3"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.004243"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw683"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13365-015-0363-x"},{"key":"e_1_3_5_23_2","first-page":"2015","article-title":"Cardiovascular complications of HIV-associated immune dysfunction","author":"Zaaqoq AM","year":"2015","unstructured":"Zaaqoq AM, , Khasawneh FA, , Smalligan RD: Cardiovascular complications of HIV-associated immune dysfunction. Cardiol Res Pract, 2015; 2015.","journal-title":"Cardiol Res Pract"},{"key":"e_1_3_5_24_2","first-page":"335","article-title":"Abacavir use and risk for myocardial infarction in the NA-ACCORD","volume":"23","author":"Palella FJ","year":"2015","unstructured":"Palella FJ, , Althoff KN, , Moore R, et al.: Abacavir use and risk for myocardial infarction in the NA-ACCORD. Top Antivir Med, 2015; 23:335\u2013336.","journal-title":"Top Antivir Med"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328354f4fb"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ327"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000879"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70271-8"},{"key":"e_1_3_5_29_2","first-page":"211","article-title":"Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs","volume":"35","author":"Quercia R","year":"2015","unstructured":"Quercia R, , Roberts J, , Martin-Carpenter L, , Zala C: Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks. Clin Drug Investig, 2015; 35:211\u2013219.","journal-title":"efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks. Clin Drug Investig"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000547"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/eci.12464"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160306"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1590\/0037-8682-0078-2016"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195942"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1080\/1354750X.2016.1204002"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.2174\/1381612822666151109111511"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2019.1636033"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku269"},{"key":"e_1_3_5_39_2","first-page":"136","article-title":"Reduction of immune activation in HIV-infected patients after introducing pitavastatin","volume":"19","author":"Morell EB","year":"2016","unstructured":"Morell EB, , Martinez M, , Bravo J, et al.: Reduction of immune activation in HIV-infected patients after introducing pitavastatin. J Int Aids Soc, 2016; 19:136.","journal-title":"J Int Aids Soc"},{"key":"e_1_3_5_40_2","first-page":"299s","article-title":"Effects of pitavastatin on atherosclerotic-associated biomarkers in people with HIV","volume":"26","author":"Phuphuakrat A","year":"2018","unstructured":"Phuphuakrat A, , Wongsa A, , Srichatrapimuk S, , Tassaneetrithep B, , Kiertiburanakul S, , Sungkanuparph S: Effects of pitavastatin on atherosclerotic-associated biomarkers in people with HIV. Top Antivir Med, 2018; 26:299s.","journal-title":"Top Antivir Med"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/tmi.12442"},{"key":"e_1_3_5_42_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001427"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328331d2ab"},{"key":"e_1_3_5_44_2","first-page":"1023","article-title":"Clinically significant drug interaction among HIV-infected patients receiving antiretroviral therapy","volume":"45","author":"So-Ngern A","year":"2014","unstructured":"So-Ngern A, , Montakantikul P, , Manosuthi W: Clinically significant drug interaction among HIV-infected patients receiving antiretroviral therapy. Southeast Asian J Trop Med Public Health, 2014; 45:1023\u20131031.","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"e_1_3_5_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2018.11.005"},{"key":"e_1_3_5_46_2","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2018.0124"},{"key":"e_1_3_5_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.12.018"},{"key":"e_1_3_5_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq111"},{"key":"e_1_3_5_49_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2012.0015"},{"key":"e_1_3_5_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chemphyslip.2018.05.005"},{"key":"e_1_3_5_51_2","first-page":"5","article-title":"Impact of rosuvastatin on atherosclerotic progression in people with HIV at moderate cardiovascular risk: A multinational, randomized, double blind, placebo-controlled trial","volume":"22","author":"Trevillyan J","year":"2019","unstructured":"Trevillyan J, , Dart A, , Cavassini M, et al.: Impact of rosuvastatin on atherosclerotic progression in people with HIV at moderate cardiovascular risk: A multinational, randomized, double blind, placebo-controlled trial. J Int Aids Soc, 2019; 22:5.","journal-title":"J Int Aids Soc"},{"key":"e_1_3_5_52_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2872"},{"issue":"1","key":"e_1_3_5_53_2","first-page":"279","article-title":"The effect of rosuvastatin on vascular disease differs by smoking status","volume":"24","author":"Hileman CO","year":"2016","unstructured":"Hileman CO, , Longenecker CT, , Labbato D, , Kinley B, , McComsey GA: The effect of rosuvastatin on vascular disease differs by smoking status. Top Antivir Med, 2016; 24(E-1):279\u2013280.","journal-title":"Top Antivir Med"},{"key":"e_1_3_5_54_2","first-page":"737","article-title":"Substitution of nevirapine or raltegravir for protease inhibitor vs","volume":"49","author":"Calza L","year":"2017","unstructured":"Calza L, , Magistrelli E, , Colangeli V, et al.: Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study). Infect Dis (Lond), 2017; 49:737\u2013747.","journal-title":"rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study). Infect Dis (Lond)"},{"key":"e_1_3_5_55_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2016.0134"},{"key":"e_1_3_5_56_2","doi-asserted-by":"publisher","DOI":"10.1310\/hct1303-153"},{"key":"e_1_3_5_57_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000478"},{"key":"e_1_3_5_58_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"e_1_3_5_59_2","unstructured":"Wells GA Shea B O'Connell D et al.: The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Non-Randomized Studies in Meta-Analyses 2008. Available from: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp accessed April16 2020."},{"key":"e_1_3_5_60_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-135"},{"key":"e_1_3_5_61_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"e_1_3_5_62_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"e_1_3_5_63_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"e_1_3_5_64_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341X.2000.00455.x"},{"key":"e_1_3_5_65_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"e_1_3_5_66_2","doi-asserted-by":"publisher","DOI":"10.1310\/hct1501-1"},{"key":"e_1_3_5_67_2","doi-asserted-by":"publisher","DOI":"10.1080\/15284336.2018.1468676"},{"key":"e_1_3_5_68_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328346be29"},{"key":"e_1_3_5_69_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu012"},{"key":"e_1_3_5_70_2","doi-asserted-by":"publisher","DOI":"10.1249\/MSS.0000000000002120"},{"key":"e_1_3_5_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2004.10.123"},{"key":"e_1_3_5_72_2","doi-asserted-by":"publisher","DOI":"10.5414\/CPP45319"},{"key":"e_1_3_5_73_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001167"},{"key":"e_1_3_5_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2013.04.025"},{"key":"e_1_3_5_75_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706738"},{"key":"e_1_3_5_76_2","first-page":"1242","article-title":"[Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia]","volume":"60","author":"G\u00f3mez-Garc\u00eda A","year":"2007","unstructured":"G\u00f3mez-Garc\u00eda A, , Mart\u00ednez Torres G, , Ortega-Pierres LE, , Rodr\u00edguez-Ayala E, , Alvarez-Aguilar C. [Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia]. Rev Esp Cardiol, 2007; 60:1242\u20131249.","journal-title":"Rev Esp Cardiol"},{"key":"e_1_3_5_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2016.09.017"},{"key":"e_1_3_5_78_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002124"},{"key":"e_1_3_5_79_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0046894"},{"key":"e_1_3_5_80_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv450"},{"key":"e_1_3_5_81_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003371"},{"key":"e_1_3_5_82_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001629"},{"key":"e_1_3_5_83_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis406"},{"key":"e_1_3_5_84_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000954"},{"key":"e_1_3_5_85_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv123"},{"key":"e_1_3_5_86_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31825b03be"},{"key":"e_1_3_5_87_2","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/pix050"},{"key":"e_1_3_5_88_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-122"},{"key":"e_1_3_5_89_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283634819"},{"key":"e_1_3_5_90_2","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2017.1311323"},{"key":"e_1_3_5_91_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky106"},{"key":"e_1_3_5_92_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32832b514b"},{"key":"e_1_3_5_93_2","first-page":"136","article-title":"Statins use is associated with greater CD4 gains in HIV-infected us veterans","volume":"22","author":"Drechsler HJ","year":"2014","unstructured":"Drechsler HJ, , Cutrell J, , Tebas P, , Bedimo R: Statins use is associated with greater CD4 gains in HIV-infected us veterans. Top Antivir Med, 2014; 22:136.","journal-title":"Top Antivir Med"},{"key":"e_1_3_5_94_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiq115"},{"key":"e_1_3_5_95_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-019-06924-7"},{"key":"e_1_3_5_96_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2013.07.012"},{"key":"e_1_3_5_97_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2019.09.160"},{"key":"e_1_3_5_98_2","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2014.5836"},{"key":"e_1_3_5_99_2","first-page":"546","article-title":"Association between statin use and plasma D-dimer levels","volume":"114","author":"Sahebkar A","year":"2015","unstructured":"Sahebkar A, , Serban C, , Mikhailidis DP, et al.: Association between statin use and plasma D-dimer levels. A systematic review and meta-analysis of randomised controlled trials. Thromb Haemost, 2015; 114:546\u2013557.","journal-title":"A systematic review and meta-analysis of randomised controlled trials. Thromb Haemost"},{"key":"e_1_3_5_100_2","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12223"},{"key":"e_1_3_5_101_2","doi-asserted-by":"publisher","DOI":"10.1111\/eci.12944"},{"key":"e_1_3_5_102_2","doi-asserted-by":"publisher","DOI":"10.2174\/138161210794455120"},{"key":"e_1_3_5_103_2","doi-asserted-by":"publisher","DOI":"10.1177\/1076029618766254"},{"key":"e_1_3_5_104_2","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13130"},{"key":"e_1_3_5_105_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy014"},{"key":"e_1_3_5_106_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001626"},{"key":"e_1_3_5_107_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001444"},{"key":"e_1_3_5_108_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.18-0322"},{"key":"e_1_3_5_109_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32833ad914"},{"key":"e_1_3_5_110_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181f7f61a"},{"key":"e_1_3_5_111_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.004312"},{"key":"e_1_3_5_112_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0152588"},{"key":"e_1_3_5_113_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090978"},{"key":"e_1_3_5_114_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv036"},{"key":"e_1_3_5_115_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2018.12.016"},{"key":"e_1_3_5_116_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2019.02.011"}],"container-title":["AIDS Research and Human Retroviruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/aid.2020.0273","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/aid.2020.0273","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/aid.2020.0273","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:15:41Z","timestamp":1777367741000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/aid.2020.0273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":115,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1089\/aid.2020.0273"],"URL":"https:\/\/doi.org\/10.1089\/aid.2020.0273","relation":{},"ISSN":["0889-2229","1931-8405"],"issn-type":[{"value":"0889-2229","type":"print"},{"value":"1931-8405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11]]}}}